ABL Diagnostics, a publicly-listed company on Euronext (FR001400AHX6 – ABLD), has announced the release of its new DeepChek®-HPV Assay and software on Thursday, January 18th, 2024. This innovative solution aims to screen, genotype, and discriminate the Human Papillomavirus (HPV), a virus known to cause genital warts and cancer. The DeepChek®-HPV Assay uses an advanced design that allows…
No responses yet